Open AccessEfficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis
Author(s) -
Ming-Yi Zhou,
Ping Yu,
Jinglei Qu,
Ying Chen,
Yang Zhou,
Lingyu Fu,
Jingdong Zhang
Publication year - 2016
Publication title -
cellular physiology and biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.486
H-Index - 87
eISSN - 1421-9778
pISSN - 1015-8987
DOI - 10.1159/000452551
Subject(s) - bevacizumab , medicine , oncology , colorectal cancer , meta analysis , chemotherapy , hazard ratio , randomized controlled trial , progression free survival , clinical trial , cancer , confidence interval
Whether patients with RAS mutation metastatic colorectal cancer (mCRC) obtain benefits from bevacizumab added to first-line chemotherapy remains unclear.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom